Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
← catalyst calendarSponsored by Janux Therapeutics (industry) · JANX — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
130estimated
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-19 | actual | When the study began enrolling |
| Primary completion | 2026-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Small Cell Lung Cancer
- Renal Cell Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Colorectal Carcinoma
- Small Cell Lung Cancer
- Pancreatic Ductal Adenocarcinoma
- Triple-negative Breast Cancer
Intervention
- Drug: JANX008
Primary outcomes
what the primary-completion date above is the date OFIncidence of Dose Limiting Toxicities (DLT)
measured 21 days
Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)
measured Up to 4 years
Incidence of Clinically Significant Laboratory Abnormalities
measured Up to 4 years
Permalink · JANX's whole pipeline · Catalyst calendar · Every registered study · What changed